REFRACTORY TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Engineered immune cells take aim at Hard-to-Treat lymphomas
Disease control OngoingThis study tests a treatment using a patient's own immune cells, modified in a lab to recognize and attack a protein called CD20 on lymphoma cells. It is for people with B-cell non-Hodgkin lymphoma that has come back or not responded to prior therapy. The goal is to find the safe…
Matched conditions: REFRACTORY TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New hope for hard-to-treat lymphoma: targeted drug combo shows promise
Disease control OngoingThis study tests a new combination of drugs (polatuzumab vedotin plus standard chemotherapy and immunotherapy) as the first treatment after lymphoma returns or doesn't respond. About 41 adults with diffuse large B-cell lymphoma will receive this therapy to see if it can shrink tu…
Matched conditions: REFRACTORY TRANSFORMED B-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated May 11, 2026 20:38 UTC